Aethlon Medical Advances Hemopurifier Trials, Raises $1.9M via ATM
Aethlon Medical is advancing its Hemopurifier, a clinical-stage immunotherapeutic device with FDA "Breakthrough Device" designation for oncology and life-threatening infectious diseases. The company is progressing with a safety, feasibility, and dose-finding clinical trial in Australia for advanced/metastatic cancer patients, having completed the first two cohorts without serious adverse events. To support operations and clinical development, Aethlon recently raised approximately $1.9 million in gross proceeds through an at-the-market (ATM) offering. However, the company's financial statements for fiscal year 2026 carry a going concern qualification, highlighting the need for additional financing and the speculative nature of investment.
Key Highlights
- Hemopurifier received FDA "Breakthrough Device" designation for advanced/metastatic cancer and life-threatening viruses.
- Completed enrollment and treatment of first two cohorts (3 participants each) in Australian oncology trial.
- No serious adverse events or dose-limiting toxicities reported in Australian oncology trial to date.
- Research and development costs were $1,912,000 in fiscal year 2026 and $2,212,000 in 2025.
- Raised approximately $1,904,000 in gross proceeds from selling 800,111 common shares via ATM facility.
- Net proceeds from ATM offering were approximately $1,851,000 after commissions and fees.
- Company holds approximately 19 issued patents and 18 pending patent applications worldwide.
Price Impact
More from AEMD